Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epogen Facing Sales Hit With Reduced Dosing Instructions In ESA Labeling For Renal Disease

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen agrees to studies to find what FDA calls "better, safer dose regimen strategies" as ESA labeling revisions create more conservative dosing guidelines for the products.
Advertisement

Related Content

GAO Tracks Decline In ESA Use Following Regulatory Changes
ESRD Market Snapshot: The Price Has To Be Right
Amgen Hits Another Emerging Market Target With $700M Turkish Deal
Groups Call On CMS To Maintain Floor Hemoglobin Target For ESRD Payment
Groups Call On CMS To Maintain Floor Hemoglobin Target For ESRD Payment
Medicare Proposes Changes To Target Hemoglobin Levels In ESRD Treatment
Medicare Proposes Changes To Target Hemoglobin Levels In ESRD Treatment
Medicare Response To ESA "Overuse" In CKD Will Await Impact Of Bundled Payments, CMS Says
Aranesp Awaits Label Transplant As Committee Mulls Alternate Trial Designs
Aranesp Awaits Label Transplant As Committee Mulls Alternate Trial Designs

Topics

Advertisement
UsernamePublicRestriction

Register

PS072418

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel